The FLT3-like Gene Expression Signature Predicts Response to Quizartinib in Wild-Type FLT3 Acute Myeloid Leukemia: An Analysis of the Pethema Quiwi TrialAdrián Mosquera Orgueira, Pau Montesinos, Pilar Herrera Puente et al.|Blood|2023Cited by 15
S130: PRELIMINARY RESULTS OF QUIWI: A DOUBLE BLINDED, RANDOMIZED CLINICAL TRIAL COMPARING STANDARD CHEMOTHERAPY PLUS QUIZARTINIB VERSUS PLACEBO IN ADULT PATIENTS WITH NEWLY DIAGNOSED FLT3-ITD WILD-TYPE AMLPau Montesinos, Jorge Labrador, Rebeca Rodríguez‐Veiga et al.|HemaSphere|2023Cited by 14
Quizartinib for Newly Diagnosed <i>FLT3</i> -Internal Tandem Duplication–Negative AML: The Randomized, Double-Blind, Placebo-Controlled, Phase II QUIWI StudyPau Montesinos, Jorge Labrador, Rebeca Rodríguez‐Veiga et al.|Journal of Clinical Oncology|2025Cited by 13
Integrated flow cytometry and sequencing to reconstruct evolutionary patterns from dysplasia to acute myeloid leukemiaCatia Simoes, Bruno Paiva, Carmen Chillón et al.|Blood Advances|2022Cited by 8
S132: UPDATED RESULTS OF VEN-A-QUI STUDY: A PHASE 1-2 TRIAL TO ASSESS THE SAFETY AND EFFICACY OF TRIPLETS FOR NEWLY DIAGNOSED UNFIT AML PATIENTS: AZACITIDINE OR LOW-DOSE CYTARABINE WITH VENETOCLAX AND QUIZARTINIBJuan Miguel Bergua Burgués, Pau Montesinos, Rebeca Rodríguez‐Veiga et al.|HemaSphere|2023Cited by 6